Cockrell Family Regents' Chair in Engineering #9
Cellular and Biomolecular Engineering
Phone: (512) 471-6975
Office: CPE 4.410
Since 2009 our laboratory has been focused on the discovery and development of protein therapeutics and on the analysis of adaptive immune responses.
Current projects include:
- Engineering and preclinical/clinical development of human enzyme therapeutics for cancer treatment.
- Development of methods for the molecular-level understanding of antibody responses to immune challenge.
- Analysis of the antibody repertoire elicited by viral infection (e.g. HIV-1) and vaccination to aid the development of more efficient vaccines.
- Engineering of antibody therapeutics displaying enhanced ability to recruit cytotoxic leukocytes and blood proteins (complement) for the effective clearance of pathogens.
Earlier work by the Georgiou lab had focused on redox homeostasis and protein biogenesis in bacteria and on the development of platform technologies for protein expression and engineering. These studies led to a number of mechanistic advances and to new technologies that are being used commercially for therapeutic protein manufacturing and protein engineering. Dr. Georgiou is co-inventor of 29 issued and 46 pending US patents. Notably, 16 different technology suites (comprising either one or multiple patents) have been licensed to majorepharmaceutical and biotechnology companies.
Select Honors, Awards
2010 Institute of Medicine (IOM) of the National Academies
2008 Elected as one of 100 Eminent Chemical Engineers of the Modern Era,
American Institute of Chemical Engineers (AIChE)
2007 AMGEN Award in Biochemical Engineering
2005 National Academy of Engineering (NAE)
2004 Fellow, American Association for the Advancement of Science
2004 Fellow, American Academy of Microbiology
2003 Professional Progress Award for Outstanding Progress in Chemical
2003 Marvin J. Johnson Award in Microbial and Biochemical Technology, American
1996 Fellow, American Institute for Biological and Medical Engineers (AIMBE)
1995 E. Bergman Award US-Israel Bi-national Science Foundation
- Doria-Rose, N.A… Georgiou, G.… P.D. Kwong and J.R. Mascola, “Developmental Pathway for Potent V1V2-Directed HIV-1-Neutralizing Antibodies,” Nature (in press, 2014)
- Georgiou G., Ippolito, G., Beuasang, G., Busse, C.E., Wardemann, H. and S.R. Quake, “The Promise and Challenge of High-throughput Sequencing of the Antibody Repertoire,” Nature Biotechnol. 32:158-68 (2014)
- Quandt, E.M., Deatherage, D.E., Ellington, A.D., Georgiou, G. and J. E. Barrick, “Recursive Genome-Wide Recombination and Sequencing Reveals a Key Refinement Step in the Evolution of a Metabolic Innovation in E. coli,” Proc. Natl. Acad. Sci. USA 111:2217-22 (2014)
- Lavinder, J., Wine, Y., Giesecke, C., Ippolito, G.C., Horton, A.P., Hoi, K.-H., DeKosky, B.J., Ellington, A.D., Dörner, T., Marcotte, E.M., Boutz, D.R. and G. Georgiou, “Dynamics, Functionality and Discordance of the Human Serum Antibody and BCR Repertoires Following Immunization” Proc. Natl. Acad. Sci. USA 111:2259-64 (2014)
- Li, Y., Gebhard, M.C., Qing, L., Georgiou, G. and B.L. Iverson, B.L., “Engineering of Novel TEV Protease Variants by Yeast ER Sequestration Screening (YESS) of Combinatorial Libraries” Proc. Natl. Acad. Sci. USA 110:7229-34 (2013)
- DeKosky, B.J., Ippolito, G.C., Deschner, R.P., Lavinder, J.J., Rawlings, M.P., Varadarajan, N., Wine, Y., Giesecke, C., Dörner, T., Andrews, S.F., Wilson, P.C., Hunicke-Smith, S.P., Wilson, C.P., Ellington, A.D. and G. Georgiou, “High Throughput Determination of the Antibody VH:VL Paired Repertoires,” Nature Biotechnol. 31:166-69 (2013)
- Wine, Y., Boutz, D.R., Lavinder, J.J., Horton, A., Miklos, A.E., Hughes, R.A., Jung, S.T, Murrin E.M., Ellington, A.D., Marcotte, E.M. and G. Georgiou, “Molecular Deconvolution of the Monoclonal Antibodies that Comprise the Polyclonal Serum Response,” Proc. Natl. Acad. Sci. USA 110: 2993-8 (2013) PMID: 23382245
- Jung, S. T., Kelton, W., Kang, T. H.; Ng, D., Anderssen, J. T.; Sandlie, I., Sarkar, C., G. Georgiou, "Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity" ACS Chem. Bio. 8:368-75 (2013)
- Stone, E.M., Paley, O., Hu, J., Ekerdt, B.; Cheung, N.-K. and G. Georgiou, “De novo Engineering of a Human Methionine-γ-Lyase for Systemic L-Met Depletion Cancer Therapy,” ACS Chem. Bio. 7:1822-9 (2012)